(October 20, 2017) An international, large scale study may have found a link between high-grade ovarian cancer and a type of white blood cell known as a tumor-infiltrating lymphocyte. Recently published in JAMA Oncology, the article from the Ovarian Tumor Tissue Analysis Consortium discussed the study, which involved about 5,500 patients, 3,196 of whom had high-grade ovarian cancer. Although it was previously established that high grade ovarian cancer tumors contain cyctotoxic CD8, a type of tumor infiltrating lymphocyte, the study found a direct correlation between the levels of CD8 and survival: the higher the CD8 level, the better the survival for patients.
“Developing a better understanding of factors that increase cytotoxic CD8 tumor-infiltrating lymphocytes will be the key to developing treatments to achieve better outcomes in treating patients with high-grade ovarian cancer,” concludes Matthew Block, MD, PhD, co leader of the team at Mayo Clinic.
Share this page
More StoriesPrev: OCRFA Funded Study Discovers 3 Key Genes in Prevention and Treatment of BRCA1 and BRCA2 Tumors Next: New Research Indicates that High Grade Serous Ovarian Carcinomas Originate in the Fallopian Tubes
C.C. C.C. Gunderson Affiliations University of Oklahoma Health Sciences Center, Department of Obstetrics and Gynecology, Division of
Gynecologic Oncology, Oklahoma City, OK, USA K.N. Slaughter K.N. Slaughter Affiliations University of Oklahoma
Health Sciences Center, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Oklahoma City, OK, USA Search for articles by this author E.D. Thomas
E.D. Thomas
Affiliations
University of Oklahoma Health Sciences Center, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Oklahoma City, OK, USA
Search for articles by this author
R. Farrell
R. Farrell
Affiliations
University of Oklahoma Health Sciences Center, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Oklahoma City, OK, USA
Search for articles by this author
K. Ding
K. Ding
Affiliations
The University of Oklahoma Health Sciences Center, College of Public Health, Department of Biostatistics and Epidemiology, Oklahoma City, OK, USA
Search for articles by this author
J.K. Lauer
J.K. Lauer
Affiliations
University of Oklahoma Health Sciences Center, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Oklahoma City, OK, USA
Search for articles by this author
L.J. Perry
L.J. Perry
Affiliations
University of Oklahoma Health Sciences Center, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Oklahoma City, OK, USA
Search for articles by this author
D.S. McMeekin
D.S. McMeekin
Affiliations
University of Oklahoma Health Sciences Center, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Oklahoma City, OK, USA
Search for articles by this author
K.N. Moore
K.N. Moore
Affiliations
University of Oklahoma Health Sciences Center, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Oklahoma City, OK, USA
Search for articles by this author
Objectives: Thrombocytosis (TBC) is often a marker of occult malignancy and is a poor prognostic factor in ovarian cancer. Shorter time to progression, decreased overall survival, and advanced stage disease have been
noted with TBC. Preoperative leukocytosis (LC) has been shown to be an independent poor prognostic factor in carcinoma of the cervix and endometrium; however, the prognosis of LC with ovary cancer is less clear. To read this article in full you will need to make a payment DOI:
//doi.org/10.1016/j.ygyno.2013.07.042 © 2013 Published by Elsevier Inc. Article Info
Identification
Copyright
ScienceDirect
Access this article on ScienceDirectRelated Articles